VivoSeq
Other

Total Neoadjuvant Therapy

0

Pipeline Programs↗

10

Active Trials↗

0

Companies Involved↗

Total Neoadjuvant Therapy is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

N/A

Attrition Rate

0/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

13

clinical trials

Not yet recruiting7 · 54%
Unknown status3 · 23%
Recruiting3 · 23%

Clinical Trials

Trial Activity

13 trials

Total Neoadjuvant Therapy in Rectal Cancer
Recruiting·NNational Cheng-Kung University Hospital·Phase 2·NCT06162650·42 enrolled
Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.
Recruiting·—·Phase 2/3·NCT06758830·400 enrolled
A Multicenter Single-arm P2 to Evaluate Safety and Efficacy of the Total Neoadjuvant Therapy for cT2 Rectal Cancer
Recruiting·OOsaka University·Phase 2·NCT05939661·45 enrolled
Short-Course Radiotherapy Combined with Intracavitary Brachytherapy Followed by Pucotenlimab, Bevacizumab, Oxaliplatin, and Trifluridine/Tipiracil (TAS-102) for Total Neoadjuvant Therapy of Microsatellite Stable (MSS) Locally Advanced Low Rectal Cancer
Not yet recruiting·SSir Run Run Shaw Hospital·Phase 2·NCT06872606·33 enrolled
Total Neoadjuvant Therapy With PD-1 for Locally Advcancer Rectal Cancer
Not yet recruiting·TThe First Affiliated Hospital of University of Science and Technology of China·Phase 2·NCT07214142·30 enrolled
Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study
Not yet recruiting·FFudan University·Phase 2·NCT06390982·46 enrolled
Organ Preservation Following Enverolimab-based Total Neoadjuvant Therapy for Locally Advanced Very Low Rectal Cancer
Not yet recruiting·—·Phase 2·NCT05969847·72 enrolled
Neoadjuvant Chemoradiotherapy Versus Total Neoadjuvant Therapy in the Treatment of T3 Rectal Cancer
Not yet recruiting·SSt. James's Hospital, Ireland·Phase 3·NCT06097416·100 enrolled
PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer
Not yet recruiting·SSun Yat-sen University·Phase 3·NCT07277842·382 enrolled
Evaluating the Impact of GLP-1 Receptor Agonists With Total Neoadjuvant Therapy in Rectal Cancer
Not yet recruiting·SSt. James's Hospital, Ireland·Phase 2·NCT07314528·42 enrolled
Brazilian Total Neoadjuvant Therapy Trial
Unknown status·HHospital Israelita Albert Einstein·Phase 3·NCT05081687·150 enrolled
Total Neoadjuvant Therapy Followed by 'Watch and Wait' Approach or Organ Preservation for Low-risk Rectal Cancer
Unknown status·PPeking University Cancer Hospital & Institute·N/A·NCT04405206·54 enrolled
Total Neoadjuvant Therapy in Rectal Cancer Treatment
Unknown status·SState Scientific Centre of Coloproctology, Russian Federation·Phase 4·NCT04747951·280 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)